Bristol-Myers Squibb Company (BMY) Q3 2026 (USD): Adj. EPS 1.35 (exp. 1.10), Revenue 13.07bln (exp. 12.72bln)

• Adj. EPS 6.35-6.55 (exp. 6.34), Revenue 49.75-50.25bln (exp. 49.9bln).

A clean top-and-bottom-line beat of this size in a large-cap pharma name typically splits the follow-through question into two parts: how much of the surprise came from the core growth portfolio versus legacy products facing generic erosion, and how much of the EPS beat is revenue-driven versus a function of cost control or a lower tax line. The raised full-year guidance, with the midpoint above prior consensus, is the part of the print that has historically carried more weight for this peer set than the quarter itself, since single-quarter beats in pharma are often absorbed by guidance that is merely reaffirmed. The distinction worth drawing is between a raise driven by new product traction, which tends to hold, and one driven by one-off items or currency, which the market has routinely discounted on previous occasions. The follow-ons are the call commentary on the key growth assets, any update on the patent-cliff bridge and pipeline readouts, and whether the sell side revises the outer years or simply rolls the beat forward. Print reaction in names of this profile has tended to fade or extend based on the guidance quality rather than the headline surprise.